PVLA

Palvella Therapeutics (PVLA)

About Palvella Therapeutics (PVLA)

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. It develops a pipeline of treatments for rare genetic skin diseases using its patented QTORIN platform. The company was founded in 2015 and is headquartered in Wayne, PA.

Details

Daily high

$105.68

Daily low

$95.00

Price at open

$99.48

52 Week High

$114.69

52 Week Low

$12.02

Market cap

1.2B

Dividend yield

0.00%

Volume

107,707

Avg. volume

303,258

P/E ratio

-7.97

Palvella Therapeutics News